Major shake-up as Nicox strives for success of novel eye drug

28 February 2024
eye_ophthalmics_ophthalmology_big-1

French ophthalmology company Nicox (Euronext:COX) has announced it will replace its chief executive, Andreas Segerros, with current chief business officer Gavin Spencer.

While the firm provided few details on the decision, the change of leadership comes as part of a broader overhaul aimed at refocusing clinical priorities and extending cash reserves.

Nicox said it had reached an agreement in principle for an amendment to existing debt agreements, extending its cash runway to November 2024.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical